Suppr超能文献

慢病毒载体制备中部分重组体的分析。

Analysis of partial recombinants in lentiviral vector preparations.

作者信息

Kuate Seraphin, Marino Michael P, Reiser Jakob

机构信息

Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research , U.S. Food and Drug Administration, Bethesda, MD 20892.

出版信息

Hum Gene Ther Methods. 2014 Apr;25(2):126-35. doi: 10.1089/hgtb.2013.015. Epub 2014 Feb 14.

Abstract

The presence of replication-competent lentivirus (RCL) in lentiviral vector preparations is a major safety concern for clinical applications of such vectors. RCL are believed to emerge from rare recombinant vector genomes that are referred to as partial recombinants or Psi-Gag recombinants. To quantitatively determine the fraction of partial recombinants in lentiviral vector preparations and to analyze them at the DNA sequence level, we established a drug selection assay involving a lentiviral packaging construct containing a drug-resistance gene encoding blasticidin (BSD) resistance. Upon transduction of target cells, the BSD resistance gene confers BSD resistance to the transduced cells. The results obtained indicate that there were up to 156 BSD-resistant colonies in a total of 10(6) transducing vector particles. The predicted recombination events were verified by polymerase chain reaction using genomic DNA obtained from BSD-resistant cell clones and by DNA sequence analysis. In an attempt to reduce the emergence of partial recombinants, sequence overlaps between the packaging and the vector constructs were reduced by substituting the Rev response element (RRE) present in the vector construct using a heterologous RRE element derived from simian immunodeficiency virus (SIVmac239). The results obtained showed that a reduction of sequence overlaps resulted in an up to sevenfold reduction of the frequency of BSD-resistant colonies, indicating that the capacity to form partial recombinants was diminished.

摘要

慢病毒载体制剂中存在具有复制能力的慢病毒(RCL)是此类载体临床应用中的一个主要安全问题。RCL被认为源自罕见的重组载体基因组,这些基因组被称为部分重组体或Psi-Gag重组体。为了定量测定慢病毒载体制剂中部分重组体的比例,并在DNA序列水平上对其进行分析,我们建立了一种药物筛选试验,该试验涉及一种慢病毒包装构建体,其包含一个编码杀稻瘟菌素(BSD)抗性的耐药基因。在转导靶细胞后,BSD抗性基因赋予转导细胞BSD抗性。获得的结果表明,在总共10^6个转导载体颗粒中,有多达156个BSD抗性菌落。通过使用从BSD抗性细胞克隆获得的基因组DNA进行聚合酶链反应以及DNA序列分析,验证了预测的重组事件。为了减少部分重组体的出现,通过使用源自猴免疫缺陷病毒(SIVmac239)的异源RRE元件替代载体构建体中存在的Rev反应元件(RRE),减少了包装构建体与载体构建体之间的序列重叠。获得的结果表明,序列重叠的减少导致BSD抗性菌落频率最多降低了七倍,这表明形成部分重组体的能力减弱了。

相似文献

1
Analysis of partial recombinants in lentiviral vector preparations.
Hum Gene Ther Methods. 2014 Apr;25(2):126-35. doi: 10.1089/hgtb.2013.015. Epub 2014 Feb 14.
2
Safety considerations in vector development.
Somat Cell Mol Genet. 2001 Nov;26(1-6):147-58. doi: 10.1023/a:1021082815013.
4
A third-generation lentivirus vector with a conditional packaging system.
J Virol. 1998 Nov;72(11):8463-71. doi: 10.1128/JVI.72.11.8463-8471.1998.
5
The HIV-1 Rev protein enhances encapsidation of unspliced and spliced, RRE-containing lentiviral vector RNA.
PLoS One. 2012;7(11):e48688. doi: 10.1371/journal.pone.0048688. Epub 2012 Nov 1.
6
A synthetic Rev-independent bovine immunodeficiency virus-based packaging construct.
Hum Gene Ther. 2004 Sep;15(9):865-77. doi: 10.1089/hum.2004.15.865.
8
Development of a novel trans-lentiviral vector that affords predictable safety.
Mol Ther. 2000 Jul;2(1):47-55. doi: 10.1006/mthe.2000.0095.
10
Novel bovine lentiviral vectors based on Jembrana disease virus.
J Gene Med. 2000 May-Jun;2(3):176-85. doi: 10.1002/(SICI)1521-2254(200005/06)2:3<176::AID-JGM106>3.0.CO;2-Q.

引用本文的文献

2
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.
Mol Ther. 2018 Jan 3;26(1):280-288. doi: 10.1016/j.ymthe.2017.09.008. Epub 2017 Sep 12.

本文引用的文献

1
Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.
Hum Gene Ther Methods. 2012 Apr;23(2):137-47. doi: 10.1089/hgtb.2012.054. Epub 2012 May 21.
3
Production of lentiviral vectors in protein-free media.
Curr Protoc Cell Biol. 2011 Mar;Chapter 26:Unit 26.8. doi: 10.1002/0471143030.cb2608s50.
4
Replication-competent lentivirus analysis of clinical grade vector products.
Mol Ther. 2011 Mar;19(3):557-66. doi: 10.1038/mt.2010.278. Epub 2010 Dec 21.
5
Risks linked to endogenous retroviruses for vaccine production: a general overview.
Biologicals. 2010 May;38(3):366-70. doi: 10.1016/j.biologicals.2010.01.006. Epub 2010 Mar 23.
6
The remarkable frequency of human immunodeficiency virus type 1 genetic recombination.
Microbiol Mol Biol Rev. 2009 Sep;73(3):451-80, Table of Contents. doi: 10.1128/MMBR.00012-09.
7
Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors.
Nat Protoc. 2009;4(4):495-505. doi: 10.1038/nprot.2009.22.
8
Recombination of retrotransposon and exogenous RNA virus results in nonretroviral cDNA integration.
Science. 2009 Jan 16;323(5912):393-6. doi: 10.1126/science.1167375.
9
Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection.
J Virol Methods. 2009 May;157(2):113-21. doi: 10.1016/j.jviromet.2008.11.021. Epub 2009 Jan 20.
10
Detection of replication competent retrovirus and lentivirus.
Methods Mol Biol. 2009;506:243-63. doi: 10.1007/978-1-59745-409-4_17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验